Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS.

Cancer Immunol Res. 2014 Apr;2(4):320-31. doi: 10.1158/2326-6066.CIR-13-0133. Epub 2013 Nov 25.

PMID:
24764579
[PubMed - in process]
2.

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.

Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED.

Clin Cancer Res. 2007 Mar 15;13(6):1757-61.

PMID:
17363529
[PubMed - indexed for MEDLINE]
Free Article
3.

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A.

Int J Cancer. 2006 Jul 15;119(2):317-27.

PMID:
16482562
[PubMed - indexed for MEDLINE]
4.

Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes.

Shabtai M, Ye H, Frischer Z, Martin J, Waltzer WC, Malinowski K.

J Urol. 2002 Nov;168(5):2216-9.

PMID:
12394762
[PubMed - indexed for MEDLINE]
5.

PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.

Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, Jacobs JF, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM.

J Immunother. 2012 Feb-Mar;35(2):169-78. doi: 10.1097/CJI.0b013e318247a4e7.

PMID:
22306905
[PubMed - indexed for MEDLINE]
6.

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.

Tykodi SS.

Onco Targets Ther. 2014 Jul 25;7:1349-59. doi: 10.2147/OTT.S48443. eCollection 2014. Review.

PMID:
25114573
[PubMed]
Free PMC Article
7.

Minimal changes in the systemic immune response after nephrectomy of localized renal masses.

Wald G, Barnes KT, Bing MT, Kresowik TP, Tomanek-Chalkley A, Kucaba TA, Griffith TS, Brown JA, Norian LA.

Urol Oncol. 2014 Jul;32(5):589-600. doi: 10.1016/j.urolonc.2014.01.023. Epub 2014 Apr 24.

PMID:
24768357
[PubMed - in process]
8.

Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.

Ning H, Shao QQ, Ding KJ, Gao DX, Lu QL, Cao QW, Niu ZH, Fu Q, Zhang CH, Qu X, Lü JJ.

Chin Med J (Engl). 2012 Jun;125(12):2120-5.

PMID:
22884140
[PubMed - indexed for MEDLINE]
Free Article
9.

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.

Sittig SP, Køllgaard T, Grønbæk K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P.

Oncoimmunology. 2013 Sep 1;2(9):e26014. Epub 2013 Sep 26.

PMID:
24228230
[PubMed]
Free PMC Article
10.

Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy.

Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM.

J Immunother. 2007 May-Jun;30(4):417-24.

PMID:
17457216
[PubMed - indexed for MEDLINE]
11.

Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

Belldegrun A, Tso CL, Kaboo R, Pang S, Pierce W, deKernion JB, Figlin R.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):149-61.

PMID:
8732698
[PubMed - indexed for MEDLINE]
12.

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.

Cancer Res. 2001 Nov 1;61(21):7925-33.

PMID:
11691814
[PubMed - indexed for MEDLINE]
Free Article
13.

T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6.

Oldham KA, Parsonage G, Bhatt RI, Wallace DM, Deshmukh N, Chaudhri S, Adams DH, Lee SP.

Eur Urol. 2012 Feb;61(2):385-94. doi: 10.1016/j.eururo.2011.10.035. Epub 2011 Nov 4.

PMID:
22079021
[PubMed - indexed for MEDLINE]
14.

Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.

Shabtai M, Ye H, Kono K, Takayam T, Terashima K, Tsukuda K, Frischer Z, Waltzer WC, Malinowski K.

Urol Oncol. 2003 Jan-Feb;21(1):27-32.

PMID:
12684124
[PubMed - indexed for MEDLINE]
15.

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS.

Int J Cancer. 2011 Feb 15;128(4):887-96. doi: 10.1002/ijc.25397.

PMID:
20473887
[PubMed - indexed for MEDLINE]
16.
17.

Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction.

Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L.

Neoplasia. 2009 Jul;11(7):662-71.

PMID:
19568411
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.

Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller B, Schulz S, Bernhard H.

Int J Cancer. 2012 May 15;130(10):2327-36. doi: 10.1002/ijc.26272. Epub 2012 Jan 11.

PMID:
21717461
[PubMed - indexed for MEDLINE]
19.

The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.

Tsavaris N, Baxevanis C, Kosmidis P, Papamichael M.

Cancer Immunol Immunother. 1996 Oct;43(2):94-102.

PMID:
8954143
[PubMed - indexed for MEDLINE]
20.

Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.

Harshman LC, Choueiri TK, Drake C, Stephen Hodi F Jr.

Cancer J. 2014 Jul-Aug;20(4):272-80. doi: 10.1097/PPO.0000000000000055.

PMID:
25098288
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk